SIB 1757

Drug Profile

SIB 1757

Alternative Names: SIB 1757 series - Merck/Novartis

Latest Information Update: 06 Sep 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co; Novartis
  • Class
  • Mechanism of Action Excitatory amino acid antagonists; Metabotropic glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders

Most Recent Events

  • 16 Dec 1999 SIBIA Neurosciences has been acquired by, and integrated into, Merck & Co.
  • 14 Apr 1998 Preclinical development for Neurological disorders (Prevention) in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top